Global Rivaroxaban Market

Rivaroxaban Comprehensive Study by Application (Deep Vein Thrombosis Prophylaxis, Pulmonary Embolism), Distribution Channel (Online, Hospital Pharmacies), Strength (2.5 mg, 10 mg, 15 mg, 20 mg) Players and Region - Global Market Outlook to 2026

Rivaroxaban Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Rivaroxaban Market Scope?
Rivaroxaban is a drug which is an oral form of a drug. It is a prescription drug. It is sold under the brand name of Xarelto and is not available as a generic drug. This drug is used to treat and prevent the blood vessels from clotting. This drug is used to prevent stroke in people, prevent and treat the blood clots in the blood vessels. The blood clots are formed in certain veins like in the legs. The clots can also travel to the lungs causing pulmonary embolisms. They also prevent deep vein thromboses after knee or hip replacement surgery. This medication also reduces the risk of major heart problems such as heart attack or stroke in coronary artery disease or peripheral artery disease. The drug is consumed in addition to aspirin to reduce the risk of major heart problems in people with chronic artery disease or peripheral artery disease. This drug was first started by Bayer AG.

The Rivaroxaban market study is being classified, by Application (Deep Vein Thrombosis Prophylaxis and Pulmonary Embolism) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from Asian will contribute to the maximum growth of Global Rivaroxaban market throughout the predicted period.

Bayer AG (Germany), Janssen Pharmaceuticals Inc. (United States), MITS Healthcare Pvt Limited (India), Wohltat Life Sciences (India), Healing Pharma India Pvt. Ltd (India), Psychocare Health Pvt Limited (India), Medicine Impex (India), SPR Oncocare Private Limited (India) and Kindcare Drugs Private Limited (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Akcent Healthcare India Private Limited (India) and Solisom Healthcare LLP (India).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Rivaroxaban market by Type, Application and Region.

On the basis of geography, the market of Rivaroxaban has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On October 30, 2017, Janssen Pharmaceuticals, Inc. had announced that the U.S. Food and Drug Administration (FDA) had approved the 10 mg once-daily dose of XARELTO® (rivaroxaban) for the purpose of reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy.


Influencing Market Trend
  • The Rising Awareness About Mental Health
  • A Rise in The Recommendation of Medical Experts to Consume the Drug to Overcome Hypertension

Market Drivers
  • Increase in The Number of Hip and Knee Replacement Surgeries
  • Expanding Clinical Preliminaries
  • Increase in Stress Levels

Opportunities
  • Growing Improvements and Developments Across the Healthcare Industry

Restraints
  • Side Effects Caused by Drugs
  • High Cost of Drugs

Challenges
  • Presence of Substitute Drugs


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Rivaroxaban, Suppliers and Distributors of Rivaroxaban, Venture Capitalists and Private Equity Firms and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Application
  • Deep Vein Thrombosis Prophylaxis
  • Pulmonary Embolism
By Distribution Channel
  • Online
  • Hospital Pharmacies

By Strength
  • 2.5 mg
  • 10 mg
  • 15 mg
  • 20 mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in The Number of Hip and Knee Replacement Surgeries
      • 3.2.2. Expanding Clinical Preliminaries
      • 3.2.3. Increase in Stress Levels
    • 3.3. Market Challenges
      • 3.3.1. Presence of Substitute Drugs
    • 3.4. Market Trends
      • 3.4.1. The Rising Awareness About Mental Health
      • 3.4.2. A Rise in The Recommendation of Medical Experts to Consume the Drug to Overcome Hypertension
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rivaroxaban, by Application, Distribution Channel, Strength and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Rivaroxaban (Value)
      • 5.2.1. Global Rivaroxaban by: Application (Value)
        • 5.2.1.1. Deep Vein Thrombosis Prophylaxis
        • 5.2.1.2. Pulmonary Embolism
      • 5.2.2. Global Rivaroxaban by: Distribution Channel (Value)
        • 5.2.2.1. Online
        • 5.2.2.2. Hospital Pharmacies
      • 5.2.3. Global Rivaroxaban by: Strength (Value)
        • 5.2.3.1. 2.5 mg
        • 5.2.3.2. 10 mg
        • 5.2.3.3. 15 mg
        • 5.2.3.4. 20 mg
      • 5.2.4. Global Rivaroxaban Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Rivaroxaban (Volume)
      • 5.3.1. Global Rivaroxaban by: Application (Volume)
        • 5.3.1.1. Deep Vein Thrombosis Prophylaxis
        • 5.3.1.2. Pulmonary Embolism
      • 5.3.2. Global Rivaroxaban by: Distribution Channel (Volume)
        • 5.3.2.1. Online
        • 5.3.2.2. Hospital Pharmacies
      • 5.3.3. Global Rivaroxaban by: Strength (Volume)
        • 5.3.3.1. 2.5 mg
        • 5.3.3.2. 10 mg
        • 5.3.3.3. 15 mg
        • 5.3.3.4. 20 mg
      • 5.3.4. Global Rivaroxaban Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Rivaroxaban (Price)
  • 6. Rivaroxaban: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Janssen Pharmaceuticals Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. MITS Healthcare Pvt Limited (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Wohltat Life Sciences (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Healing Pharma India Pvt. Ltd (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Psychocare Health Pvt Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Medicine Impex (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. SPR Oncocare Private Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Kindcare Drugs Private Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Rivaroxaban Sale, by Application, Distribution Channel, Strength and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Rivaroxaban (Value)
      • 7.2.1. Global Rivaroxaban by: Application (Value)
        • 7.2.1.1. Deep Vein Thrombosis Prophylaxis
        • 7.2.1.2. Pulmonary Embolism
      • 7.2.2. Global Rivaroxaban by: Distribution Channel (Value)
        • 7.2.2.1. Online
        • 7.2.2.2. Hospital Pharmacies
      • 7.2.3. Global Rivaroxaban by: Strength (Value)
        • 7.2.3.1. 2.5 mg
        • 7.2.3.2. 10 mg
        • 7.2.3.3. 15 mg
        • 7.2.3.4. 20 mg
      • 7.2.4. Global Rivaroxaban Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Rivaroxaban (Volume)
      • 7.3.1. Global Rivaroxaban by: Application (Volume)
        • 7.3.1.1. Deep Vein Thrombosis Prophylaxis
        • 7.3.1.2. Pulmonary Embolism
      • 7.3.2. Global Rivaroxaban by: Distribution Channel (Volume)
        • 7.3.2.1. Online
        • 7.3.2.2. Hospital Pharmacies
      • 7.3.3. Global Rivaroxaban by: Strength (Volume)
        • 7.3.3.1. 2.5 mg
        • 7.3.3.2. 10 mg
        • 7.3.3.3. 15 mg
        • 7.3.3.4. 20 mg
      • 7.3.4. Global Rivaroxaban Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Rivaroxaban (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rivaroxaban: by Application(USD Million)
  • Table 2. Rivaroxaban Deep Vein Thrombosis Prophylaxis , by Region USD Million (2015-2020)
  • Table 3. Rivaroxaban Pulmonary Embolism , by Region USD Million (2015-2020)
  • Table 4. Rivaroxaban: by Distribution Channel(USD Million)
  • Table 5. Rivaroxaban Online , by Region USD Million (2015-2020)
  • Table 6. Rivaroxaban Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 7. Rivaroxaban: by Strength(USD Million)
  • Table 8. Rivaroxaban 2.5 mg , by Region USD Million (2015-2020)
  • Table 9. Rivaroxaban 10 mg , by Region USD Million (2015-2020)
  • Table 10. Rivaroxaban 15 mg , by Region USD Million (2015-2020)
  • Table 11. Rivaroxaban 20 mg , by Region USD Million (2015-2020)
  • Table 12. South America Rivaroxaban, by Country USD Million (2015-2020)
  • Table 13. South America Rivaroxaban, by Application USD Million (2015-2020)
  • Table 14. South America Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 15. South America Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 16. Brazil Rivaroxaban, by Application USD Million (2015-2020)
  • Table 17. Brazil Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 18. Brazil Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 19. Argentina Rivaroxaban, by Application USD Million (2015-2020)
  • Table 20. Argentina Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 21. Argentina Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 22. Rest of South America Rivaroxaban, by Application USD Million (2015-2020)
  • Table 23. Rest of South America Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 24. Rest of South America Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 25. Asia Pacific Rivaroxaban, by Country USD Million (2015-2020)
  • Table 26. Asia Pacific Rivaroxaban, by Application USD Million (2015-2020)
  • Table 27. Asia Pacific Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 28. Asia Pacific Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 29. China Rivaroxaban, by Application USD Million (2015-2020)
  • Table 30. China Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 31. China Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 32. Japan Rivaroxaban, by Application USD Million (2015-2020)
  • Table 33. Japan Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 34. Japan Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 35. India Rivaroxaban, by Application USD Million (2015-2020)
  • Table 36. India Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 37. India Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 38. South Korea Rivaroxaban, by Application USD Million (2015-2020)
  • Table 39. South Korea Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 40. South Korea Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 41. Taiwan Rivaroxaban, by Application USD Million (2015-2020)
  • Table 42. Taiwan Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 43. Taiwan Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 44. Australia Rivaroxaban, by Application USD Million (2015-2020)
  • Table 45. Australia Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 46. Australia Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Rivaroxaban, by Application USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 50. Europe Rivaroxaban, by Country USD Million (2015-2020)
  • Table 51. Europe Rivaroxaban, by Application USD Million (2015-2020)
  • Table 52. Europe Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 53. Europe Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 54. Germany Rivaroxaban, by Application USD Million (2015-2020)
  • Table 55. Germany Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 56. Germany Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 57. France Rivaroxaban, by Application USD Million (2015-2020)
  • Table 58. France Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 59. France Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 60. Italy Rivaroxaban, by Application USD Million (2015-2020)
  • Table 61. Italy Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 62. Italy Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 63. United Kingdom Rivaroxaban, by Application USD Million (2015-2020)
  • Table 64. United Kingdom Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 65. United Kingdom Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 66. Netherlands Rivaroxaban, by Application USD Million (2015-2020)
  • Table 67. Netherlands Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 68. Netherlands Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 69. Rest of Europe Rivaroxaban, by Application USD Million (2015-2020)
  • Table 70. Rest of Europe Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 71. Rest of Europe Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 72. MEA Rivaroxaban, by Country USD Million (2015-2020)
  • Table 73. MEA Rivaroxaban, by Application USD Million (2015-2020)
  • Table 74. MEA Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 75. MEA Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 76. Middle East Rivaroxaban, by Application USD Million (2015-2020)
  • Table 77. Middle East Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 78. Middle East Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 79. Africa Rivaroxaban, by Application USD Million (2015-2020)
  • Table 80. Africa Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 81. Africa Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 82. North America Rivaroxaban, by Country USD Million (2015-2020)
  • Table 83. North America Rivaroxaban, by Application USD Million (2015-2020)
  • Table 84. North America Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 85. North America Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 86. United States Rivaroxaban, by Application USD Million (2015-2020)
  • Table 87. United States Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 88. United States Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 89. Canada Rivaroxaban, by Application USD Million (2015-2020)
  • Table 90. Canada Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 91. Canada Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 92. Mexico Rivaroxaban, by Application USD Million (2015-2020)
  • Table 93. Mexico Rivaroxaban, by Distribution Channel USD Million (2015-2020)
  • Table 94. Mexico Rivaroxaban, by Strength USD Million (2015-2020)
  • Table 95. Rivaroxaban Sales: by Application(K Tons)
  • Table 96. Rivaroxaban Sales Deep Vein Thrombosis Prophylaxis , by Region K Tons (2015-2020)
  • Table 97. Rivaroxaban Sales Pulmonary Embolism , by Region K Tons (2015-2020)
  • Table 98. Rivaroxaban Sales: by Distribution Channel(K Tons)
  • Table 99. Rivaroxaban Sales Online , by Region K Tons (2015-2020)
  • Table 100. Rivaroxaban Sales Hospital Pharmacies , by Region K Tons (2015-2020)
  • Table 101. Rivaroxaban Sales: by Strength(K Tons)
  • Table 102. Rivaroxaban Sales 2.5 mg , by Region K Tons (2015-2020)
  • Table 103. Rivaroxaban Sales 10 mg , by Region K Tons (2015-2020)
  • Table 104. Rivaroxaban Sales 15 mg , by Region K Tons (2015-2020)
  • Table 105. Rivaroxaban Sales 20 mg , by Region K Tons (2015-2020)
  • Table 106. South America Rivaroxaban Sales, by Country K Tons (2015-2020)
  • Table 107. South America Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 108. South America Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 109. South America Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 110. Brazil Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 111. Brazil Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 112. Brazil Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 113. Argentina Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 114. Argentina Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 115. Argentina Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 116. Rest of South America Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 117. Rest of South America Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 118. Rest of South America Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 119. Asia Pacific Rivaroxaban Sales, by Country K Tons (2015-2020)
  • Table 120. Asia Pacific Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 121. Asia Pacific Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 122. Asia Pacific Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 123. China Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 124. China Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 125. China Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 126. Japan Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 127. Japan Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 128. Japan Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 129. India Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 130. India Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 131. India Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 132. South Korea Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 133. South Korea Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 134. South Korea Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 135. Taiwan Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 136. Taiwan Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 137. Taiwan Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 138. Australia Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 139. Australia Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 140. Australia Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 141. Rest of Asia-Pacific Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 142. Rest of Asia-Pacific Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 143. Rest of Asia-Pacific Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 144. Europe Rivaroxaban Sales, by Country K Tons (2015-2020)
  • Table 145. Europe Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 146. Europe Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 147. Europe Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 148. Germany Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 149. Germany Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 150. Germany Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 151. France Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 152. France Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 153. France Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 154. Italy Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 155. Italy Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 156. Italy Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 157. United Kingdom Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 158. United Kingdom Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 159. United Kingdom Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 160. Netherlands Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 161. Netherlands Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 162. Netherlands Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 163. Rest of Europe Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 164. Rest of Europe Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 165. Rest of Europe Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 166. MEA Rivaroxaban Sales, by Country K Tons (2015-2020)
  • Table 167. MEA Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 168. MEA Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 169. MEA Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 170. Middle East Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 171. Middle East Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 172. Middle East Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 173. Africa Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 174. Africa Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 175. Africa Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 176. North America Rivaroxaban Sales, by Country K Tons (2015-2020)
  • Table 177. North America Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 178. North America Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 179. North America Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 180. United States Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 181. United States Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 182. United States Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 183. Canada Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 184. Canada Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 185. Canada Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 186. Mexico Rivaroxaban Sales, by Application K Tons (2015-2020)
  • Table 187. Mexico Rivaroxaban Sales, by Distribution Channel K Tons (2015-2020)
  • Table 188. Mexico Rivaroxaban Sales, by Strength K Tons (2015-2020)
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Rivaroxaban: by Application(USD Million)
  • Table 199. Rivaroxaban Deep Vein Thrombosis Prophylaxis , by Region USD Million (2021-2026)
  • Table 200. Rivaroxaban Pulmonary Embolism , by Region USD Million (2021-2026)
  • Table 201. Rivaroxaban: by Distribution Channel(USD Million)
  • Table 202. Rivaroxaban Online , by Region USD Million (2021-2026)
  • Table 203. Rivaroxaban Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 204. Rivaroxaban: by Strength(USD Million)
  • Table 205. Rivaroxaban 2.5 mg , by Region USD Million (2021-2026)
  • Table 206. Rivaroxaban 10 mg , by Region USD Million (2021-2026)
  • Table 207. Rivaroxaban 15 mg , by Region USD Million (2021-2026)
  • Table 208. Rivaroxaban 20 mg , by Region USD Million (2021-2026)
  • Table 209. South America Rivaroxaban, by Country USD Million (2021-2026)
  • Table 210. South America Rivaroxaban, by Application USD Million (2021-2026)
  • Table 211. South America Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 212. South America Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 213. Brazil Rivaroxaban, by Application USD Million (2021-2026)
  • Table 214. Brazil Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 215. Brazil Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 216. Argentina Rivaroxaban, by Application USD Million (2021-2026)
  • Table 217. Argentina Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 218. Argentina Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 219. Rest of South America Rivaroxaban, by Application USD Million (2021-2026)
  • Table 220. Rest of South America Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 221. Rest of South America Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 222. Asia Pacific Rivaroxaban, by Country USD Million (2021-2026)
  • Table 223. Asia Pacific Rivaroxaban, by Application USD Million (2021-2026)
  • Table 224. Asia Pacific Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 225. Asia Pacific Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 226. China Rivaroxaban, by Application USD Million (2021-2026)
  • Table 227. China Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 228. China Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 229. Japan Rivaroxaban, by Application USD Million (2021-2026)
  • Table 230. Japan Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 231. Japan Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 232. India Rivaroxaban, by Application USD Million (2021-2026)
  • Table 233. India Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 234. India Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 235. South Korea Rivaroxaban, by Application USD Million (2021-2026)
  • Table 236. South Korea Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 237. South Korea Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 238. Taiwan Rivaroxaban, by Application USD Million (2021-2026)
  • Table 239. Taiwan Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 240. Taiwan Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 241. Australia Rivaroxaban, by Application USD Million (2021-2026)
  • Table 242. Australia Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 243. Australia Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 244. Rest of Asia-Pacific Rivaroxaban, by Application USD Million (2021-2026)
  • Table 245. Rest of Asia-Pacific Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 246. Rest of Asia-Pacific Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 247. Europe Rivaroxaban, by Country USD Million (2021-2026)
  • Table 248. Europe Rivaroxaban, by Application USD Million (2021-2026)
  • Table 249. Europe Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 250. Europe Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 251. Germany Rivaroxaban, by Application USD Million (2021-2026)
  • Table 252. Germany Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 253. Germany Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 254. France Rivaroxaban, by Application USD Million (2021-2026)
  • Table 255. France Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 256. France Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 257. Italy Rivaroxaban, by Application USD Million (2021-2026)
  • Table 258. Italy Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 259. Italy Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 260. United Kingdom Rivaroxaban, by Application USD Million (2021-2026)
  • Table 261. United Kingdom Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 262. United Kingdom Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 263. Netherlands Rivaroxaban, by Application USD Million (2021-2026)
  • Table 264. Netherlands Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 265. Netherlands Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 266. Rest of Europe Rivaroxaban, by Application USD Million (2021-2026)
  • Table 267. Rest of Europe Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 268. Rest of Europe Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 269. MEA Rivaroxaban, by Country USD Million (2021-2026)
  • Table 270. MEA Rivaroxaban, by Application USD Million (2021-2026)
  • Table 271. MEA Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 272. MEA Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 273. Middle East Rivaroxaban, by Application USD Million (2021-2026)
  • Table 274. Middle East Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 275. Middle East Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 276. Africa Rivaroxaban, by Application USD Million (2021-2026)
  • Table 277. Africa Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 278. Africa Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 279. North America Rivaroxaban, by Country USD Million (2021-2026)
  • Table 280. North America Rivaroxaban, by Application USD Million (2021-2026)
  • Table 281. North America Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 282. North America Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 283. United States Rivaroxaban, by Application USD Million (2021-2026)
  • Table 284. United States Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 285. United States Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 286. Canada Rivaroxaban, by Application USD Million (2021-2026)
  • Table 287. Canada Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 288. Canada Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 289. Mexico Rivaroxaban, by Application USD Million (2021-2026)
  • Table 290. Mexico Rivaroxaban, by Distribution Channel USD Million (2021-2026)
  • Table 291. Mexico Rivaroxaban, by Strength USD Million (2021-2026)
  • Table 292. Rivaroxaban Sales: by Application(K Tons)
  • Table 293. Rivaroxaban Sales Deep Vein Thrombosis Prophylaxis , by Region K Tons (2021-2026)
  • Table 294. Rivaroxaban Sales Pulmonary Embolism , by Region K Tons (2021-2026)
  • Table 295. Rivaroxaban Sales: by Distribution Channel(K Tons)
  • Table 296. Rivaroxaban Sales Online , by Region K Tons (2021-2026)
  • Table 297. Rivaroxaban Sales Hospital Pharmacies , by Region K Tons (2021-2026)
  • Table 298. Rivaroxaban Sales: by Strength(K Tons)
  • Table 299. Rivaroxaban Sales 2.5 mg , by Region K Tons (2021-2026)
  • Table 300. Rivaroxaban Sales 10 mg , by Region K Tons (2021-2026)
  • Table 301. Rivaroxaban Sales 15 mg , by Region K Tons (2021-2026)
  • Table 302. Rivaroxaban Sales 20 mg , by Region K Tons (2021-2026)
  • Table 303. South America Rivaroxaban Sales, by Country K Tons (2021-2026)
  • Table 304. South America Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 305. South America Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 306. South America Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 307. Brazil Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 308. Brazil Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 309. Brazil Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 310. Argentina Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 311. Argentina Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 312. Argentina Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 313. Rest of South America Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 314. Rest of South America Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 315. Rest of South America Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 316. Asia Pacific Rivaroxaban Sales, by Country K Tons (2021-2026)
  • Table 317. Asia Pacific Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 318. Asia Pacific Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 319. Asia Pacific Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 320. China Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 321. China Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 322. China Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 323. Japan Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 324. Japan Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 325. Japan Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 326. India Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 327. India Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 328. India Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 329. South Korea Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 330. South Korea Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 331. South Korea Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 332. Taiwan Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 333. Taiwan Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 334. Taiwan Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 335. Australia Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 336. Australia Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 337. Australia Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 338. Rest of Asia-Pacific Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 339. Rest of Asia-Pacific Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 340. Rest of Asia-Pacific Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 341. Europe Rivaroxaban Sales, by Country K Tons (2021-2026)
  • Table 342. Europe Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 343. Europe Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 344. Europe Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 345. Germany Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 346. Germany Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 347. Germany Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 348. France Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 349. France Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 350. France Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 351. Italy Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 352. Italy Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 353. Italy Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 354. United Kingdom Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 355. United Kingdom Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 356. United Kingdom Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 357. Netherlands Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 358. Netherlands Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 359. Netherlands Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 360. Rest of Europe Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 361. Rest of Europe Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 362. Rest of Europe Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 363. MEA Rivaroxaban Sales, by Country K Tons (2021-2026)
  • Table 364. MEA Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 365. MEA Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 366. MEA Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 367. Middle East Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 368. Middle East Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 369. Middle East Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 370. Africa Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 371. Africa Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 372. Africa Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 373. North America Rivaroxaban Sales, by Country K Tons (2021-2026)
  • Table 374. North America Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 375. North America Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 376. North America Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 377. United States Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 378. United States Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 379. United States Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 380. Canada Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 381. Canada Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 382. Canada Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 383. Mexico Rivaroxaban Sales, by Application K Tons (2021-2026)
  • Table 384. Mexico Rivaroxaban Sales, by Distribution Channel K Tons (2021-2026)
  • Table 385. Mexico Rivaroxaban Sales, by Strength K Tons (2021-2026)
  • Table 386. Research Programs/Design for This Report
  • Table 387. Key Data Information from Secondary Sources
  • Table 388. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rivaroxaban: by Application USD Million (2015-2020)
  • Figure 5. Global Rivaroxaban: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Rivaroxaban: by Strength USD Million (2015-2020)
  • Figure 7. South America Rivaroxaban Share (%), by Country
  • Figure 8. Asia Pacific Rivaroxaban Share (%), by Country
  • Figure 9. Europe Rivaroxaban Share (%), by Country
  • Figure 10. MEA Rivaroxaban Share (%), by Country
  • Figure 11. North America Rivaroxaban Share (%), by Country
  • Figure 12. Global Rivaroxaban: by Application K Tons (2015-2020)
  • Figure 13. Global Rivaroxaban: by Distribution Channel K Tons (2015-2020)
  • Figure 14. Global Rivaroxaban: by Strength K Tons (2015-2020)
  • Figure 15. South America Rivaroxaban Share (%), by Country
  • Figure 16. Asia Pacific Rivaroxaban Share (%), by Country
  • Figure 17. Europe Rivaroxaban Share (%), by Country
  • Figure 18. MEA Rivaroxaban Share (%), by Country
  • Figure 19. North America Rivaroxaban Share (%), by Country
  • Figure 20. Global Rivaroxaban share by Players 2020 (%)
  • Figure 21. Global Rivaroxaban share by Players (Top 3) 2020(%)
  • Figure 22. Global Rivaroxaban share by Players (Top 5) 2020(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 26. Janssen Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Janssen Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 28. MITS Healthcare Pvt Limited (India) Revenue, Net Income and Gross profit
  • Figure 29. MITS Healthcare Pvt Limited (India) Revenue: by Geography 2020
  • Figure 30. Wohltat Life Sciences (India) Revenue, Net Income and Gross profit
  • Figure 31. Wohltat Life Sciences (India) Revenue: by Geography 2020
  • Figure 32. Healing Pharma India Pvt. Ltd (India) Revenue, Net Income and Gross profit
  • Figure 33. Healing Pharma India Pvt. Ltd (India) Revenue: by Geography 2020
  • Figure 34. Psychocare Health Pvt Limited (India) Revenue, Net Income and Gross profit
  • Figure 35. Psychocare Health Pvt Limited (India) Revenue: by Geography 2020
  • Figure 36. Medicine Impex (India) Revenue, Net Income and Gross profit
  • Figure 37. Medicine Impex (India) Revenue: by Geography 2020
  • Figure 38. SPR Oncocare Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 39. SPR Oncocare Private Limited (India) Revenue: by Geography 2020
  • Figure 40. Kindcare Drugs Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 41. Kindcare Drugs Private Limited (India) Revenue: by Geography 2020
  • Figure 42. Global Rivaroxaban: by Application USD Million (2021-2026)
  • Figure 43. Global Rivaroxaban: by Distribution Channel USD Million (2021-2026)
  • Figure 44. Global Rivaroxaban: by Strength USD Million (2021-2026)
  • Figure 45. South America Rivaroxaban Share (%), by Country
  • Figure 46. Asia Pacific Rivaroxaban Share (%), by Country
  • Figure 47. Europe Rivaroxaban Share (%), by Country
  • Figure 48. MEA Rivaroxaban Share (%), by Country
  • Figure 49. North America Rivaroxaban Share (%), by Country
  • Figure 50. Global Rivaroxaban: by Application K Tons (2021-2026)
  • Figure 51. Global Rivaroxaban: by Distribution Channel K Tons (2021-2026)
  • Figure 52. Global Rivaroxaban: by Strength K Tons (2021-2026)
  • Figure 53. South America Rivaroxaban Share (%), by Country
  • Figure 54. Asia Pacific Rivaroxaban Share (%), by Country
  • Figure 55. Europe Rivaroxaban Share (%), by Country
  • Figure 56. MEA Rivaroxaban Share (%), by Country
  • Figure 57. North America Rivaroxaban Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Janssen Pharmaceuticals Inc. (United States)
  • MITS Healthcare Pvt Limited (India)
  • Wohltat Life Sciences (India)
  • Healing Pharma India Pvt. Ltd (India)
  • Psychocare Health Pvt Limited (India)
  • Medicine Impex (India)
  • SPR Oncocare Private Limited (India)
  • Kindcare Drugs Private Limited (India)
Additional players considered in the study are as follows:
Akcent Healthcare India Private Limited (India) , Solisom Healthcare LLP (India)
Select User Access Type

Key Highlights of Report


Dec 2021 205 Pages 95 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Rivaroxaban Market Quantitative research analysis
Global Rivaroxaban Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Rivaroxaban market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Rivaroxaban market are Bayer AG (Germany), Janssen Pharmaceuticals Inc. (United States), MITS Healthcare Pvt Limited (India), Wohltat Life Sciences (India), Healing Pharma India Pvt. Ltd (India), Psychocare Health Pvt Limited (India), Medicine Impex (India), SPR Oncocare Private Limited (India) and Kindcare Drugs Private Limited (India), to name a few.
In this highly competitive & fast evolving Rivaroxaban industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Rivaroxaban Market Report?

Have a Query? Click Here

Other Related Reports

Revivable Yeast Comprehensive Study by Application (Food and Beverages, Cosmetics and Skincare, Pharmaceuticals, Other), Nature (Organic, Conventional), Form (Powder, Paste, Tablet, Capsule, Other), ...
$ 3450
Ampicillin Drugs Comprehensive Study by Indication (Infection (Intestine, Stomach, Bladder, and Others), Meningitis, Gonorrhea, Pneumonia, Others), Distribution Channel (Hospital Pharmacies, Retail P...
$ 3450
Heartworm Treatment Products Comprehensive Study by Type (Chewable (Fluralaner, Valerian, Chamomile), Spot on (Methoprene, Fipronil, Moxidectin)), Application (Dog, Cats, Others), Distribution Channe...
$ 3450
Constipation Laxative Comprehensive Study by Type (Bulk-forming Laxatives, Osmotic Laxatives, Stimulant Laxatives, Stool Softener Laxatives, Others (Lubricant laxatives, Saline laxatives, and Prokine...
$ 3750
Tribulus Terrestris Extract Comprehensive Study by Nature (Organic, Conventional), Form (Powder, Liquid Capsules, Liquid Syrup, Tinctures), End Use (Pharmaceuticals, Dietary Supplement, Others) Playe...
$ 3500
Etanercept Drugs Comprehensive Study by Application (Arthritis, Psoriasis, Spondylitis), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2026
$ 3500